Table 2. Pathological tumour characteristics in patients identified as bearing insignificant PC by the selection tools described.
| Tosoian | Adamy | Van den Bergh | Whitson | Soloway | Selvadurai | D'Amico | Any criteria | All criteria | |
|---|---|---|---|---|---|---|---|---|---|
| Patients, n (%) |
44 (10.7) |
146 (35.6) |
63 (15.4) |
169 (41.2) |
106 (25.9) |
306 (74.6) |
206 (49.6) |
339 (82.7) |
43 (10.5) |
|
Pathological Gleason score,
n
(%) | |||||||||
| 2-6 | 28 (6.8) | 85 (20.7) | 41 (10.0) | 93 (22.7) | 58 (14.1) | 151 (36.8) | 109 (28.6) | 169 (41.2) | 27 (6.6) |
| 7 | 14 (3.4) | 57 (13.9) | 20 (4.9) | 71 (17.3) | 44 (10.7) | 145 (35.4) | 91 (21.8) | 160 (39.0) | 14 (3.4) |
| 8-10 |
2 (0.5) |
4 (1.0) |
2 (0.5) |
5 (1.2) |
4 (1.0) |
10 (2.4) |
6 (1.4) |
10 (2.4) |
2 (0.5) |
|
Pathological stage,
n
(%) | |||||||||
| ⩾pT3 | 3 (0.7) | 28 (6.8) | 6 (1.5) | 39 (9.5) | 14 (3.5) | 90 (22.0) | 71 (17.4) | 106 (25.9) | 3 (0.7) |
| ⩾pT3b | 0 (0.0) | 2 (0.5) | 1 (0.2) | 2 (0.5) | 2 (0.5) | 7 (1.7) | 3 (0.7) | 7 (1.7) | 0 (0.0) |
| Positive margins, n (%) | 3 (0.7) | 25(6.1) | 7 (1.7) | 33 (8.1) | 16 (3.9) | 58 (14.2) | 46 (11.3) | 65 (15.9) | 3 (0.7) |
| Tumour volume, cc, median (IQR) | 1.7 (1.0–3.1) | 2.7 (1.3–4.7) | 2.5 (1.1–3.9) | 2.9 (1.5–5.3) | 2.4 (1.1–4.6) | 3.4 (1.8–6.3) | 3.0 (1.7–5.4) | 3.6 (1.9–6.5) | 1.6 (1.0–3.2) |
| Largest tumour volume (where multiple tumours), cc, median (IQR) | 1.3 (0.9–2.3) | 2.2 (1.0–3.5) | 1.8 (0.8–3.2) | 2.5 (1.1–3.8) | 1.9 (1.0–3.7) | 2.8 (1.5–4.4) | 2.7 (1.5–4.4) | 3.0 (1.6–5.2) | 1.4 (0.7–2.6) |
| Insignificant cancers, classical definition, n (%) | 3 (0.7) | 9 (2.2) | 3 (0.7) | 9 (2.2) | 8 (2.0) | 12 (2.9) | 9 (2.2) | 12 (2.9) | 3 (0.7) |
| Insignificant cancers, ERSPC definition, n (%) | 17 (4.2) | 45 (11.0) | 22 (5.4) | 47 (11.5) | 36 (8.8) | 66 (16.1) | 51 (12.3) | 73 (17.8) | 16 (3.9) |
| Organ-confined low-grade cancer, n (%) | 28 (6.8) | 81 (19.8) | 39 (9.5) | 88 (21.5) | 57 (13.9) | 134 (32.7) | 97 (23.4) | 147 (35.9) | 27 (6.6) |
Abbreviations: ERSPC=European Randomised Study of screening for prostate cancer; IQR=interquartile range; PC=prostate cancer.